EN DE
Watch DNA Link Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

DNA Link Inc (127120) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of DNA Link Inc stock KRW 18,003, price KRW 17,440, upside +3.2%, quality 26 out of 100. Rating: fairly valued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7127120004

DL DNA Link Inc logo Thin data Nov 5, 2026

DNA Link Inc

127120 · KQ
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Low debt
Revenue last quarter +64% vs. a year ago.
Fair value 18,003 KRW · Fairly valued (+3.2%)
Mixed Growth (revenue 5y +4.8 %/yr in KRW)
Quality 26/100
Loss-making · -23.3% net margin (TTM)
Negative free cash flow
Trails peers (3/10)
Narrow moat 9/100
Thin data
⚠ Dilution
Watch DNA Link Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

48,900 KRW 2,385 KRW Fair Value 18,003 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.

How to read this chart

60‑month range 2,385 KRW – 48,900 KRW · fair‑value band 11,876 KRW – 22,498 KRW · the 17,440 KRW price screens below the 18,003 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.

Follow DNA Link in your weekly email

Every Wednesday you see whether DNA Link is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally.

Show moreShow less

Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing.

The company also provides microarray services, such as DNA and microarray RNA analysis; Fluidigm BioMark System, an automated PCR/qPCR system; TaqMan assay; and SNaPshot assay. In addition, it provides rare earth and permanent magnets.

The company was formerly known as DNA Link, Inc. and changed its name to JS Link, Inc. in April 2025. JS Link, Inc. was founded in 2000 and is headquartered in Seoul, South Korea.

Stock analysis

DNA Link Inc (127120) currently trades at 17,440 KRW, while our model-based Fair Value estimate is 18,003 KRW, so the stock looks roughly fairly valued today (gap 3.1%).

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.

Scenario range: 11,876 KRW (bear) to 22,498 KRW (bull), the price of 17,440 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

DNA Link Inc reported revenue of 19.3B KRW in FY2025 versus 23.0B KRW in FY2021, a compound −4.3%/yr. Reported net income was −16.4B KRW in FY2025.

Key figures

Market cap 595B KRW (≈ $436M) Small · P/S ratio 27.4 · EPS (TTM) −152.51 KRW · Net margin −23.3% · Return on equity −7.4% · Return on assets (EBIT) −17.3% (5-year average) · Operating margin −66.0% · Revenue (TTM) 22.8B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 64% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 3%, 127120 screens richer than that median.

Fair Value models

Bear 11,876 KRW Fair Value 18,003 KRW Bull 22,498 KRW
Price 17,440 KRW · Upside +3.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 13,972 KRW 21,180 KRW 26,468 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 13,972 KRW 21,180 KRW 26,468 KRW 54

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 26/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 50
Are margins and returns getting better?
Cashflow 2
Do the profits arrive as real cash?
Financial strength 88
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 47
How calm the share price moves, does not count
Price momentum 19
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 10
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 8/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+21.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.8%
Start year 2020 (pandemic). Over 10 years: +7.4% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−69.1% (2020) → −63.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 127120, get fair value alerts →

Compare DNA Link Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 26 · Bottom 25%
Fair Value upside +3.2% · Top 25%
Profitability
Return on assets −13.4% · Below median
Net margin (12 months) −23.3% · Below median
Operating margin (12 months) −66.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 64.4% · Top 25%
Balance sheet
Debt / equity 0.07× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 8.67× · Priciest 25%
P/S (12 months) 26.10× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)38 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)96 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs 127120
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs 127120
Genmab A/S GMAB kr 3,527 kr 3,999 +13% vs 127120
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs 127120
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs 127120
Vertex Pharmaceuticals Incorporated VRTX $547.09 $596.75 +9% vs 127120
argenx SE ARGX $927.21 $908.40 −2% vs 127120
CSL Limited CSL A$202.04 A$183.04 −9% vs 127120
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs 127120
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs 127120

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

DNA Link Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "DNA Link Inc Fair Value". https://www.fairvalue-calculator.com/stock/127120

Frequently asked questions

Is DNA Link Inc (127120) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of 18,003 KRW versus a price of 17,440 KRW, about +3% upside (fairly valued).
What is the fair value of 127120?
Our model-based fair value for DNA Link Inc is 18,003 KRW (as of Nov 5, 2026), built from audited fundamentals. The current price: 17,440 KRW.
What is the quality score of 127120?
DNA Link Inc has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DNA Link Inc (127120)?
Our model-based price target is the fair value of 18,003 KRW (as of Nov 5, 2026) from 1 valuation models. Cautious scenario 11,876 KRW, optimistic scenario 22,498 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the DNA Link Inc stock forecast for 2026?
Our models put fair value at 18,003 KRW, about +3% upside versus a price of 17,440 KRW (fairly valued). Cautious scenario 11,876 KRW, optimistic scenario 22,498 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of DNA Link Inc (127120)?
DNA Link Inc reported trailing-twelve-month revenue of about 22.8B KRW (latest available figure, as of Nov 5, 2026).
What is the intrinsic value of DNA Link Inc (127120)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DNA Link Inc it is 18,003 KRW per share (as of Nov 5, 2026), against a price of 17,440 KRW. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is DNA Link Inc stock overvalued or undervalued in 2026?
As of Nov 5, 2026, 127120 trades below its calculated fair value: price 17,440 KRW, fair value 18,003 KRW, a gap of about +3% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 127120?
No. The price is what the market pays today (17,440 KRW); the fair value is what the company's own numbers justify (18,003 KRW). For DNA Link Inc the two are 562.66 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is DNA Link Inc worth?
The market values DNA Link Inc at about 595B KRW (market capitalisation, as of Nov 5, 2026). Per share that is 17,440 KRW; our models calculate a fair value of 18,003 KRW per share.
What do the bullish and bearish scenarios say about 127120?
Our models span a range for DNA Link Inc: cautious scenario 11,876 KRW, base 18,003 KRW, optimistic 22,498 KRW per share (as of Nov 5, 2026, price 17,440 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of DNA Link Inc (127120)?
Balance-sheet figures for DNA Link Inc (as of Nov 5, 2026): return on equity −7.4%, debt of 0.07 per unit of equity. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is 127120 from its 52-week high?
DNA Link Inc trades at 17,440 KRW, about 64% below its 52-week high of 48,900 KRW and 9% above the low of 16,050 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 18,003 KRW is for.
Which stocks are comparable to DNA Link Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DNA Link Inc stock attractive at the current price?
The data as of Nov 5, 2026: price 17,440 KRW, calculated fair value 18,003 KRW (+3%), Quality Score 26/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 127120 calculated?
We run DNA Link Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 18,003 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. DNA Link Inc currently trades 3% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DNA Link Inc (127120)?
The closing price on Nov 6, 2026 was 17,440 KRW. Our model-based fair value is 18,003 KRW, about +3% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DNA Link Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (11,876 KRW to 22,498 KRW) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of DNA Link Inc

How large is the market capitalisation of DNA Link Inc (127120)?
The market capitalisation of DNA Link Inc is 595B KRW (≈ $436M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DNA Link Inc (127120)?
The price-to-sales ratio of DNA Link Inc is 27.4 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of DNA Link Inc (127120)?
Earnings per share at DNA Link Inc are −152.51 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of DNA Link Inc (127120)?
The net margin of DNA Link Inc is −23.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DNA Link Inc (127120)?
The return on equity (ROE) of DNA Link Inc is −7.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DNA Link Inc (127120)?
On an EBIT basis the return on assets of DNA Link Inc is −17.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DNA Link Inc (127120)?
The operating margin of DNA Link Inc is −66.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DNA Link Inc (127120)?
Revenue at DNA Link Inc is growing +64.4% versus a year earlier (3y avg +4.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does DNA Link Inc (127120) generate?
The free cash flow of DNA Link Inc is −53.5B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does DNA Link Inc (127120) carry?
The net debt of DNA Link Inc is 2.1B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch DNA Link Inc in the live analysis

One click puts DNA Link Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.